📊 TXMD Key Takeaways
Is TherapeuticsMD, Inc. (TXMD) a Good Investment?
TherapeuticsMD faces severe financial distress with -$8.7M annual operating cash burn, only $7.5M cash reserves, and excessive $93.6M long-term debt that is 3.48x equity and 2.5x total assets. While 35.3% revenue growth and 43.1% gross margin demonstrate product-market traction, the company's deep unprofitability and inability to service debt from operations creates critical solvency risk with less than one year of cash runway absent additional capital or dramatic cost restructuring.
Why Buy TherapeuticsMD, Inc. Stock? TXMD Key Strengths
- Revenue growing 35.3% YoY demonstrates market demand for commercialized products
- 43.1% gross margin indicates viable product unit economics and pricing power
- Current ratio of 3.02x and quick ratio of 1.62x provide near-term liquidity buffer
TXMD Stock Risks: TherapeuticsMD, Inc. Investment Risks
- Operating cash flow of -$8.7M annually with only $7.5M cash creates <1 year runway without external funding
- Long-term debt of $93.6M is dangerously leveraged relative to $37.7M assets and $26.9M equity (3.48x debt-to-equity)
- Interest coverage ratio of -548.8x indicates company cannot service debt from operations; debt restructuring or bankruptcy risk is material
Key Metrics to Watch
- Monthly operating cash burn trajectory and path to profitability or breakeven
- Debt refinancing announcements and covenant compliance status
- Revenue per-dollar of operating expense and gross-to-operating margin expansion
TherapeuticsMD, Inc. (TXMD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.02x current ratio provides a solid financial cushion.
TXMD Profit Margin, ROE & Profitability Analysis
TXMD vs Healthcare Sector: How TherapeuticsMD, Inc. Compares
How TherapeuticsMD, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is TherapeuticsMD, Inc. Stock Overvalued? TXMD Valuation Analysis 2026
Based on fundamental analysis, TherapeuticsMD, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
TherapeuticsMD, Inc. Balance Sheet: TXMD Debt, Cash & Liquidity
TXMD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: TherapeuticsMD, Inc.'s revenue has grown significantly by 261% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.19 indicates the company is currently unprofitable.
TXMD Revenue Growth, EPS Growth & YoY Performance
TXMD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $547.0K | $50.0K | $0.00 |
| Q2 2025 | $234.0K | -$102.0K | $-0.01 |
| Q1 2025 | $313.0K | -$653.0K | $-0.06 |
| Q3 2023 | -$53.0K | -$2.4M | $-0.32 |
| Q2 2023 | $348.0K | -$2.4M | $-0.24 |
| Q1 2023 | $416.0K | -$3.6M | $-0.37 |
| Q3 2022 | $20.9M | -$29.0M | $-3.13 |
| Q2 2022 | $23.0M | -$39.4M | $-5.41 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
TherapeuticsMD, Inc. Dividends, Buybacks & Capital Allocation
TXMD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for TherapeuticsMD, Inc. (CIK: 0000025743)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TXMD
What is the AI rating for TXMD?
TherapeuticsMD, Inc. (TXMD) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TXMD's key strengths?
Claude: Revenue growing 35.3% YoY demonstrates market demand for commercialized products. 43.1% gross margin indicates viable product unit economics and pricing power.
What are the risks of investing in TXMD?
Claude: Operating cash flow of -$8.7M annually with only $7.5M cash creates <1 year runway without external funding. Long-term debt of $93.6M is dangerously leveraged relative to $37.7M assets and $26.9M equity (3.48x debt-to-equity).
What is TXMD's revenue and growth?
TherapeuticsMD, Inc. reported revenue of $3.0M.
Does TXMD pay dividends?
TherapeuticsMD, Inc. does not currently pay dividends.
Where can I find TXMD SEC filings?
Official SEC filings for TherapeuticsMD, Inc. (CIK: 0000025743) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TXMD's EPS?
TherapeuticsMD, Inc. has a diluted EPS of $-0.05.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TXMD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, TherapeuticsMD, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TXMD stock overvalued or undervalued?
Valuation metrics for TXMD: ROE of -2.1% (sector avg: 15%), net margin of -18.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TXMD stock in 2026?
Our dual AI analysis gives TherapeuticsMD, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TXMD's free cash flow?
TherapeuticsMD, Inc.'s operating cash flow is $-8.7M, with capital expenditures of $21.0K. FCF margin is -288.6%.
How does TXMD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -18.8% (avg: 12%), ROE -2.1% (avg: 15%), current ratio 3.02 (avg: 2).
Is TherapeuticsMD, Inc. carrying too much debt?
TXMD has a debt-to-equity ratio of 3.48x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 3.02 suggests adequate short-term liquidity.